Article

Alcon launches new generation ReSTOR

Alcon, Inc has launched the +3.0 Add Power AcrySof ReSTOR aspheric intraocular lens (IOL) with blue light filter. The lens completed CE mark approval in the third quarter of 2007 and will be available throughout the EU beginning next week.

Alcon has launched the +3.0 Add Power AcrySof ReSTOR aspheric intraocular lens (IOL) with natural chromophore. The lens completed CE mark approval in the third quarter of 2007 and will be available throughout the EU beginning next week; it is currently undergoing review by the FDA for marketing in the US, and it is hoped that approval will be gained by early 2009.

The original AcrySof ReSTOR aspheric platform, which is used to treat presbyopia in cataract patients, was introduced in 2007. The +3.0 Add Power IOL is a refinement of the +4.0 Add Power lens model, and offers a broader range of visual acuity improvement options to ophthalmologists and patients.

The +3.0 lens can be inserted through a 2.2 mm incision, and does not require any extra training on the part of the surgeon, as the lens is implanted in exactly the same manner as the +4.0 add lens as the geometry and design of the lenses is identical.

The lens has been associated with a similar incidence and degree of adverse events as the +4.0 add lens, and has a high rate of patient satisfaction: 96% of the 138 patients who were implanted with the +3.0 IOL during clinical trials said that they would, given the chance, have the same lens implanted again. On a scale of 0.0 to 4.0, patient satisfaction before cataract surgery was 0.5; following bilateral implantation with the +3.0 lens, this increased to 3.4. The rate of success is also high: at three months, 94.9% of patients had best corrected visual acuities (near, intermediate and distance combined) of ≥20/40.

"We're really excited to be hearing the feedback from the physicians that have been using ReSTOR," Steve Speares, Alcon's vice president of global cataract marketing, told Ophthalmology Times Europe. "The response to the +3.0 add lens has been very positive. Even surgeons who have been happy with the +4.0 add lens have been pleased with the +3.0 add. It's resonating very well. The reaction that we've seen here at ESCRS has reconfirmed to us that we're on the right path with this.

"We're going to continue to make the ophthalmology community understand that we're not afraid to go forward across the frontier into this new arena, which is rife with opportunity," he concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.